Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
2018-001661-17Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lasmiditan in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Headache pain freedom. Status: unknown.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2018-001661-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001661-17.